epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

JAMA Ophthalmol

GLP-1 drugs linked to increased risk of neovascular AMD

June 11, 2025

card-image

Study details: This population-based cohort study used administrative health data from Ontario, Canada, to assess whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with the development of neovascular age-related macular degeneration (nAMD). The study included 46,334 patients exposed to GLP-1 RAs for at least six months, matched 1:2 with 92,668 unexposed diabetic controls.

Results: Over a mean follow-up of 2.4 years, patients taking GLP-1 RAs for at least 6 months had a significantly higher incidence of nAMD compared with controls (adjusted hazard ratio [HR], 2.21; 95% confidence interval [CI], 1.65–2.96). However, the absolute risk was small, reaching 0.2% at 3 years among GLP-1 RA users and 0.1% among non-users.

Clinical impact: These findings raise important safety considerations for long-term GLP-1 RA use, particularly in older adults at risk for AMD. Weigh the ocular risks when prescribing GLP-1 RAs and consider regular ophthalmologic monitoring for patients on prolonged therapy.

Source:

Shor R, et al. (2025, June 5). JAMA Ophthalmol. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration. https://pubmed.ncbi.nlm.nih.gov/40471562/

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information